Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue

B. Chini, M. Chinol, P. Cassoni, S. Papi, A. Reversi, L. Areces, T. Marrocco, G. Paganelli, M. Manning, G. Bussolati

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the deamino derivative of Lys 8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (I) it forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related Via, VIb and V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor intemalisation and (4) when radiolabelled, [111In]-DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours.

Original languageEnglish
Pages (from-to)930-936
Number of pages7
JournalBritish Journal of Cancer
Volume89
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

Oxytocin Receptors
Vasotocin
Oxytocin
Neoplasms
Vasopressin Receptors
Chelating Agents
Ligands

Keywords

  • LVT
  • OT
  • Oxytcocin receptor
  • Radioligand
  • Tumours

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue. / Chini, B.; Chinol, M.; Cassoni, P.; Papi, S.; Reversi, A.; Areces, L.; Marrocco, T.; Paganelli, G.; Manning, M.; Bussolati, G.

In: British Journal of Cancer, Vol. 89, No. 5, 01.09.2003, p. 930-936.

Research output: Contribution to journalArticle

Chini, B. ; Chinol, M. ; Cassoni, P. ; Papi, S. ; Reversi, A. ; Areces, L. ; Marrocco, T. ; Paganelli, G. ; Manning, M. ; Bussolati, G. / Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue. In: British Journal of Cancer. 2003 ; Vol. 89, No. 5. pp. 930-936.
@article{ea912034fefa41dd91aad985b49f29fd,
title = "Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue",
abstract = "Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the deamino derivative of Lys 8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (I) it forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related Via, VIb and V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor intemalisation and (4) when radiolabelled, [111In]-DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours.",
keywords = "LVT, OT, Oxytcocin receptor, Radioligand, Tumours",
author = "B. Chini and M. Chinol and P. Cassoni and S. Papi and A. Reversi and L. Areces and T. Marrocco and G. Paganelli and M. Manning and G. Bussolati",
year = "2003",
month = "9",
day = "1",
doi = "10.1038/sj.bjc.6601189",
language = "English",
volume = "89",
pages = "930--936",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue

AU - Chini, B.

AU - Chinol, M.

AU - Cassoni, P.

AU - Papi, S.

AU - Reversi, A.

AU - Areces, L.

AU - Marrocco, T.

AU - Paganelli, G.

AU - Manning, M.

AU - Bussolati, G.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the deamino derivative of Lys 8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (I) it forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related Via, VIb and V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor intemalisation and (4) when radiolabelled, [111In]-DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours.

AB - Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the deamino derivative of Lys 8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (I) it forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related Via, VIb and V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor intemalisation and (4) when radiolabelled, [111In]-DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours.

KW - LVT

KW - OT

KW - Oxytcocin receptor

KW - Radioligand

KW - Tumours

UR - http://www.scopus.com/inward/record.url?scp=0141507050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141507050&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601189

DO - 10.1038/sj.bjc.6601189

M3 - Article

C2 - 12942128

AN - SCOPUS:0141507050

VL - 89

SP - 930

EP - 936

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -